Optimizing efficacy of amphotericin B through nanomodification by Vyas, Suresh P & Gupta, Swati
© 2006 Dove Medical Press Limited.   All rights reserved
International Journal of Nanomedicine 2006:1(4) 417–432 417
REVIEW
Optimizing efﬁ  cacy of amphotericin B through 
nanomodiﬁ  cation
Suresh P Vyas
Swati Gupta
Drug Delivery Research Laboratory, 
Department of Pharmaceutical 
Sciences, Dr Hari Singh Gour 
University, Sagar (M.P), India
Correspondence: Suresh P Vyas
Drug Delivery Research Laboratory, 
Department of Pharmaceutical Sciences, 
Dr Hari Singh Gour University, 
Sagar (M.P) 470 003, India
Telefax: +917582 265525
E-mail: vyas_sp@rediffmail.com;
spvyas@sancharnet.in
Abstract: Fungal infections and leishmaniasis are an important cause of morbidity and mortality 
in immunocompromised patients. The macrolide polyene antibiotic amphotericin B (AmB) has 
long been recognized as a powerful fungicidal and leishmanicidal drug. A conventional intrave-
nous dosage form of AmB, AmB- deoxycholate (Fungizone or D-AmB), is the most effective 
clinically available for treating fungal and parasitic (leishmaniasis) infections. However, the 
clinical efﬁ  cacy of AmB is limited by its adverse effects mainly nephrotoxicity. Efforts to lower 
the toxicity are based on synthesis of AmB analogues such as AmB esters or preparation of 
AmB-lipid associations in the forms of liposomal AmB (L-AmB or AmBisome), AmB lipid 
complex (Abelcet or ABLC), AmB colloidal dispersion (Amphocil or ABCD), and intralipid 
AmB. These newer formulations are substantially more expensive, but allow patients to receive 
higher doses for longer periods of time with decreased renal toxicity than conventional AmB. 
Modiﬁ  cations of liposomal surface in order to avoid RES uptake, thus increased targetability 
has been attempted. Emulsomes and other nanoparticles are special carrier systems for intracel-
lular localization in macrophage rich organs like liver and spleen. Injectable nano-carriers have 
important potential applications as in site-speciﬁ  c drug delivery.
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Introduction
Systemic fungal infections may randomly be divided into two wide categories: endemic 
diseases such as histoplasmosis, coccidioidomyosis, and blastomycosis; and opportu-
nistic diseases such as cryptococcosis, aspergillosis, and candidosis, which occur almost 
entirely in patient with impaired host defenses. Antifungal therapy is based on several 
factors, such as the causative agent, the succession or incursion of the disease, and so 
on. Antifungal therapy may have to be administered empirically in febrile neutropenic 
patients who do not respond to treatment with antibacterial drugs (Medoff et al 1992). 
Antifungal agents are considerably fewer in number because of emergence of newer 
pathogenic fungi causing deep-seated mycosis. Clinically used major groups of anti-
fungal agents are polyene antibiotics, azole derivatives, allylamines-thiocarbamates, 
morpholines and miscellaneous compounds such as 5-ﬂ  uorocytosine and griseofulvin. 
Polyenes and azoles are most commonly used. Polyene antifungal agents used for 
the treatment of human diseases are amphotericin B (AmB) nystatin and natamycin. 
The only parenteral preparation with broad range of antifungal activity is AmB. Over 
the past several years, augmented efforts in both basic and clinical antifungal phar-
macology have resulted in a number of exclusively new, reengineered or reconsidered 
compounds, which are at various stages of preclinical and early clinical development 
(Hay 1994; Georgopapadakou and Walsh 1996; Maesaki 2002).
Similarly, leishmaniasis causes high morbidity and mortality worldwide which is 
escalating due to its spread as a HIV-associated infection (Alvar et al 1997; Herwaldt 
1999; Murray 1999). Due to serious side-effects of pentavalent antimonials (the ﬁ  rst-
line treatment) such as cardiac and renal toxicity and failures, and development of International Journal of Nanomedicine 2006:1(4) 418
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resistant strains in prevalent areas many practitioners have 
turned to conventional AmB, a very active antifungal agent, 
for ﬁ  rst-line therapy, which remains almost 100% effective 
(Pearson and Sousa 1996; Alvar et al 1997; Sereno et al 
2000). Since the parasites are found only within reticulo-
endotelial macrophages, the disease is preferably suited for 
drug delivery therapy. Therefore, the new AmB lipid-based 
formulations (AmBisome, Abelcet, and Amphocil) have 
been proposed for the treatment of visceral leishmaniasis 
(VL) (Davidson et al 1991; Berman et al 1992; Paul et al 
1997). The results indicated that these AmB carriers were 
effective at lower doses with abridged toxicity as compared 
to the conventional AmB formulation. The US Food and 
Drug Administration approved L-AmB for the treatment 
of VL and higly recommended their use for resistant VL in 
immunocompromised patients (Meyerhoff 1999; Espuelas 
et al 2002).
Recently, drug delivery systems (DDS) have received 
substantial attention in the ﬁ  eld of drug development. 
In DDS, pharmacological techniques are used to control 
pharmacokinetic properties (absorption, distribution, 
metabolism, and excretion) and to improve the efﬁ  cacy and 
safety of a drug. Lipid formulations, such as liposomes and 
emulsion based carriers, are very highly predictable and 
are now explored in numerous directions, and several prod-
ucts have already been made commercially available 
(Tomii 2002).
In this review the enhancement of the efﬁ  cacy of AmB 
is addressed using lipid-based nanocarriers and paying 
particular attention towards current commercial liposomal 
formulations.
Parent amphotericin B
AmB, a lipophilic polyene antifungal agent, was initially 
secluded from a strain of Streptomyces nodosus in 1956 by 
Gold et al (Gold et al 1956). It is an amphoteric compound 
composed of a hydrophilic polyhydroxyl chain along one 
side and a lipophilic polyene hydrocarbon chain on the 
other (Hoeprich 1992). AmB is poorly soluble in water 
(Storm and van Etten 1997). The drug became available 
commercially as Fungizone (Bristol-Myers-Squibb, USA) 
in 1960 as a colloidal suspension of AmB in which the bile 
salt deoxycholate was used as the solubilizing agent (Arikan 
and Rex 2001).
Role and mechanisms
The interaction of AmB with membrane sterol changes 
the membrane permeability, which in turn leads to cellular 
dysfunction and eventually to cell destruction and death 
(Bolard et al 1991; Legrand et al 1992). AmB inhibits 
mem-brane enzymes like proton ATPase in fungal cells 
(Surarit and Shepherd 1987) and Na+/K+-ATPase in 
mammalian cells (Vertut-Doı et al 1988) and this inhibi-
tory activity depletes cellular energy reserves and reduces 
proliferative ability (Schindler et al 1993). Another pos-
sible mechanism by which membrane permeability changes 
occur is AmB-induced lipid peroxidation of cell membranes 
(Brajtburg et al 1985). Likewise, binding of AmB to low-
density lipoprotein (LDL) and its consequent internalization 
modulate its toxicity (Brajtburg and Bolard 1996).
Pharmacology and adverse effects
Klepser et al obtained the time-kill curves for AmB against 
Candida albicans (Klepser et al 1997) and showed that AmB 
displays concentration-dependent fungicidal activity. Andes 
(Andes 1999) investigated the pharmacodynamics of AmB in 
neutropenic mice with disseminated candidiasis and showed 
non-linear kinetics, in vivo concentration-dependent killing, 
and prolonged concentration-dependent post-antibiotic 
effects (PAEs) of AmB. The efﬁ  cacy of AmB is compro-
mised by a high frequency of adverse effects, including fever, 
chills, nausea, vomiting, headache, and renal dysfuntion 
with associated anemia, hypokalemia, and hypomagnesemia 
(Hiemenz and Walsh 1996).
Role of lipid formulations
There are three ways by which the therapeutic index of 
AmB might be improved: (i) increasing the selectivity 
of polyene-induced damage to fungal, as opposed to 
mammalian, cells; (ii) decreasing toxicity to host cells bear-
ing LDL receptors; and (iii) decreasing toxicity for cells of 
the immune system, thereby protecting the immunostimula-
tory activity. Approaches designed to address these three 
issues involve the preparation of AmB-lipid associations. 
Therefore, there has been substantial exploration into 
the development of less toxic preparations of AmB. For 
the past decade, investigators have evaluated the use of 
colloidal dispersions and phospholipids vesicles known as 
liposomes as a targeted drug delivery systems for AmB. 
These efforts have led to the expansion of commercial 
preparations of phospholipid vesicles for therapeutic use 
such as AmBisome, ABLC, and ABCD (Hiemenz and 
Walsh 1996; Wong-Beringer et al. 1998). These prepara-
tions have been shown to be less toxic than AmB and to 
display altered pharmacokinetic properties because they 
are concentrated in the organs of the reticulo-endothelial International Journal of Nanomedicine 2006:1(4) 419
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system, but not in the kidney where only low concentrations 
are achieved (Kretschmar et al 2001).
Selected characteristics of lipid formulations that 
have been studied thoroughly and are in clinical trials are 
summarized in Table 1.
Intermediaries of antifungal 
and antiparasitic activity
Macrophages may function as a reservoir of AmB for 
intracellular and extracellular antimicrobial action. Mehta 
et al (1997) conducted a study to investigate the role of 
macrophages in candidacidal activity of L-AmB. The 
results suggested that the improved candidacidal activ-
ity of L-AmB was possibly not due to activation of the 
macrophages. Instead, higher uptake and retention of 
L-AmB and its slow release from the macrophages led to 
its improved candidacidal activity. When lipids associ-
ated AmB is taken into macrophages (Legrand et al 1996; 
Mehta et al 1994) or monocytes, it may function to inhibit 
fungal or parasitic cells also present inside these cells or 
it may dissociate from the complex inside the phagocytic 
cell and exit as free AmB to inhibit extracellular microbes 
(Figure 1). If the AmB-lipid bond is strong, AmB will 
dissociate slowly as a monomer. The monomer, then, would 
be active against fungal and parasitic cells and not toxic 
to mammalian cells.
Effects of lipid-based carrier constructs 
on AmB Binding to lipoproteins
and its internalization
AmB binding to lipoproteins may persuade the ability of 
mammalian cells to internalize the drug. If the AmB-carrier 
bond is weak and labile, as is presented in Figure 2 then when 
the complex is diluted in blood, AmB will dissociate from 
the lipid carrier and bind to LDL, just as AmB in Fungizone 
does when it dissociates from deoxycholate. The LDL-AmB 
complex can be internalized into cells bearing LDL receptors, 
and toxic effects comparable to those observed with 
Fungizone will occur.
When the AmB-carrier complex is strong and inert, it 
remains intact after introduction into the bloodstream but 
can still bind lipoproteins. ABLC may bind to highdensity 
Table 1 Characteristics of some lipid formulations under clinical trials.
AmB preparation Composition 
(mol%), charge 
of phospholipidsb
Shape and diam 
(μm)
Bioavailability 
compared with 
Fungizone
Clinical trial 
references
Fungizone D-AmB (7:3), negative Micelles,  0.4
Liposomes 
(L-AmB5, L-AmB10)
DMPC-DMPG-AmB 
(7:3:0.5,7:3:1), negative
Multilamellar 
vesicles + sheets, 1–6
Lower Emminger et al 1994; 
Lopez-Berestein 1987; 
Lopez-Berestein et al 1987; 
Lopez-Berestein et al 1985; 
Lopez-Berestein and 
Juliano 1987; 
Ralph et al 1993
AmB-lipid complex 
(ABLC,   Abelcet)
DMPC-DMPG-AmB 
(7:3:3), negative
Sheets, 1.6–11 Lower de Marie et al 1994; 
Fromtling 1995; 
Janoff et al 1993
Ampholiposomes EPC-CHOL-SA-AmB 
(4:3:1:0.5), positive
Oligolamellar vesicles, 
0.2–0.3
Greater Meunier et al 1988; 
Sculier et al 1989
AmBisome HSPC-CHOL-DSPG-AmB 
(2:1:0.8:0.4), negative
Small unilamellar 
vesicles, 0.06
Greater de Marie et al 1994
L-AmB SPC-CHOL-AmB 
(7:3:1), neutral
Small unilamellar 
vesicles
Equal Gokhale et al 1993; 
Gokhale et al 1993
AmB-colloidal 
dispersion 
(ABCD,   Amphocil)
CS-AmB (1:1), negative Discs, 0.12 Lower de Marie et al 1994; 
Fromtling 1993; 
Guo and Working 1993; 
Stevens 1994
Adapted from Brajtburg and Bolard (1996). 
Abbreviations: D, deoxycholate; CHOL, cholesterol; SA, stearylamine; HSPC, hydrogenated phosphatidylcholine; DSPG, distearoyl phosphatidylglycerol; CS, cholesteryl sulfate; 
DMPC and DMPG, dimyristoyl phosphatidylcholine and glycerol respectively.International Journal of Nanomedicine 2006:1(4) 420
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lipoproteins (HDL) and remain in the bloodstream, lacking 
toxicity (Wasan et al 1994). On the other hand, neither ABCD 
(Guo and Working 1993) nor AmB incorporated into egg 
lecithin-bile salts mixed micelles (Brajtburg et al 1994) binds 
to lipoproteins, and both are relatively nontoxic (Brajtburg 
and Bolard 1996).
Liposomal amphotericin B [L-AmB]
In 1965, Bangham et al (1965) reported that a small closed 
vesicular structure, consisted of lipid bilayers could be 
formed when phospholipids are hydrated by the addition of 
water. These structures were ﬁ  rst named as “smectic meso-
phases” by Bangham and later called ‘liposomes’ by Gerald 
Weissman (Ostro and Cullis 1989; Bangham 1992). In 1981, 
New et al. (New et al 1981) ﬁ  rst examined the effects of 
L-AmB, using leishmania model and reported that L-AmB 
had a lower toxicity than AmB itself and the treatment with 
a higher dose of L-AmB could be feasible. Afterward, the 
validity of the L-AmB for mice histoplasmosis (Taylor et al 
1982), cryptococcosis (Graybill et al 1982), and candidia-
sis (Lopez-Berestein et al 1983; Tremblay et al 1984) was 
assessed. In all cases, the L-AmB showed a lower toxicity 
than AmB to the host animals and thus could be admin-
istered at higher doses. Drugs incorporated in liposome 
were also shown to distribute mainly to reticuloendothelial 
tissues including liver, spleen, and lung (Abra and Hunt 
1981). Later, a clinical trial performed in cancer patients 
who co-developed fungal infection confirmed that the 
L-AmB showed a higher tolerance than AmB even in human 
(Lopez-Berestein et al 1985).
AmBisome
Early evaluations were performed using the MLV-type 
agents. In 1987, Szoka et al prepared the Small unilamellar 
vesicles (SCV) containing sterol and explored the effects 
of component substances of liposome and a size of the 
particle on the expression of toxicity (Szoka et al 1987). 
They concluded that the sterol including L-AmB was less toxic 
than that without sterol. They also reported that, when sterol 
was integrated, the smaller liposome was less toxic than the 
larger liposome and that, when sterol was excluded in contrast, 
the larger particle was less toxic than the smaller particle. 
Based on these ﬁ  ndings, NeXtar Inc. succeeded in formulat-
ing the SUV type L-AmB (AmBisome). AmBisome has been 
licensed for use in Europe for over 5 years. It received FDA 
approval on 11th August 1997 for the treatment of patients 
with aspergillosis, candidiasis, and/or cryptococcal infections 
refractory or intolerant to AmB.
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Figure 1 Several pathways by which lipid formulations of AmB are thought to reach fungal or parasitic cells.International Journal of Nanomedicine 2006:1(4) 421
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General Properties
Among the new generation lipid-associated AmB formulations 
being developed throughout the world, the only true liposo-
mal form of AmB is AmBisome. AmBisome is a suspension 
of small unilamellar liposomes in buffered 9% sucrose whose 
composition is HSPC (hydrogenated soya phosphatidyl 
choline)/Chol/DSPG/AmB (2:1:0.8:0.4 mole ratio). AmB is 
anchored tightly in the AmBisome bilayer due to favorable 
interactions of the macrolide with the surrounding lipids. 
DSPG probably interacts directly with AmB; cholesterol may 
also play a role. The exact nature of these interactions is not 
known, but the data are consistent with a barrel like structure 
formed by AmB molecules. Two barrels ﬁ  t together tail to 
tail to span the lipid bilyer and form a pore that is permeable 
to ions and other solutes (Figure 3). The product is stored as 
a lyophilized powder that is reconstituted with the addition 
of water for injection followed by the few seconds of shak-
ing to produce a slightly opalescent, yellow solution. In its 
lyophilized presentation, stored at 4°C, AmBisome has a 
shelf life in excess of 30 months (Schmidt et al 1998).
Mechanism of action
AmBisome has been tested in mammalian cell toxicity assay 
and has proved to be remarkable benign. Rat cell lysis assays 
are a measure of free (or readily available) AmB. Fungizone 
produced 92% lysis of rat cells in two hours at 37°C at a 
drug concentration of 1 μg/ml. AmBisome produced only 
5% lysis under the same conditions and time of incubation 
even at high concentration of 100 μg/ml (AmB equivalent). 
These data suggest that AmB is retained sufﬁ  ciently tightly 
inside the AmBisome so that less than 1% of the drug is free 
(or loose enough to be transferred to mammalian cells) in 
buffer. Potentially the association of AmB with AmBisome 
is dependent on the concentration of liposomes, if there exist 
equilibrium between free and liposome bound drug. But, in 
buffer, even as low as 1 μg/ml, the drug remains exclusively 
with the liposome as evidenced by circular dichroism studies 
over a range of concentrations (Fujii 1996). In vitro studies in 
human and mouse serum show complete retention of AmB by 
AmBisome for 6–24 hours. For AmBisome in vivo there is 
evidence that AmB is largely retained by the liposome over 
several hours of circulation in mice (van Etten et al 1995). 
Certainly the drug is not available in a free or toxic form 
since the LD50 of AmBisome is greater than 160 mg/kg in 
this species, as compared to 2.3 mg/kg for D-AmB.
There is evidence that AmBisome (and liposomes of the 
same composition without drug) can gain direct access to 
sites of fungal infection as intact structures probably because 
of leaky vasculature. The assumption has been made that 
with the prolong circulation life time seen for AmBisome, 
uptake into infected tissue and direct action of the liposomal 
drug may contribute to therapy (Adler-Moore et al 1993). 
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Figure 2 Several pathways by which the lipid formulations of AmB may reach mammalian cells.International Journal of Nanomedicine 2006:1(4) 422
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Indeed, AmBisome is highly active against cultured fungal 
species (Anaissie et al 1991), although the liposomal drug 
may be somewhat slower acting than D-AmB (van Etten et al 
1995). The liposomes, with or without drug bind to fungal 
cells, and AmBisome (but not drug free liposomes) disin-
tegrates slowly. Gold labeled lipids incorporated in AmBi-
some like liposomes can be located by electron microscopy 
(after silver enhancement). Initially intact liposomes are 
seen gathered around and bound to the cell wall of Candida 
glabrata. After 14 hours, incubation, gold labeled lipid is 
seen inside the cell membrane. The cell structure appears 
disrupted at this point, presumably due to action of AmB that 
accompanies breakup of the liposome (Adler-Moore 1994). 
While it appears feasible for AmBisome to act directly on 
systemic fungal infections, the quantitative contribution of 
intact liposomes to the success of systemic treatment with 
AmBisome needs further study. Macrophages, including 
kupffer cells of the liver and stationary macrophage in the 
spleen, are a major cellular site for uptake of AmBisome and 
other lipid-associated AmB preparations (Hartsel and Bolard 
1996). It is likely that macrophages and possibly neutrophils 
play key roles as depots for AmB, although the details have 
not been elucidated (Schmidt et al 1998).
Pharmacology, efﬁ  cacy- and toxicity 
during preclinical trials
Boswell et al (Boswell et al 1998) examined the single- and 
multiple-dose pharmacokinetics and toxicological proﬁ  le 
of AmBisome in rats. Rats were administered AmBisome 
at doses of 1, 3, 9, and 20 mg/kg/day. Substantial plasma 
concentrations (380 and 500 μg/mL in females and males, 
respectively) were attained after AmBisome therapy of 
20 mg/kg for 30 days. The results suggested that, 100-fold 
higher plasma concentrations of AmB could be attained 
with AmBisome at doses up to 20 mg/kg/day as compared 
to conventional AmB. Unlike the conventional preparation, 
AmBisome at high doses resulted in slight nephrotoxicity 
but moderate hepatotoxicity. Another study showed that 
in brain tissue of noninfected rabbits, AmBisome attained 
mean tissue levels 4–7 times higher than that with D-AmB, 
ABCD, or ABLC. Conversely, none of the lipid formulations 
nor the conventional AmB can attain detectable levels in 
cerebrospinal ﬂ  uid (CSF) in the absence of meningocerebral 
inﬂ  ammation. Nevertheless, the high level of AmBisome 
attained in brain tissue is potentially promising for its future 
use in fungal infections of central nervous system (Groll 
et al 1997). The efﬁ  cacy of D-AmB compared to those of 
the lipid formulations in murine cryptococcosis also showed 
that AmBisome was one of the most efﬁ  cacious formulations 
(Clemons and Stevens 1998).
The results of in vitro experiments against common 
pathogens including Candida, Cryptococcus, Aspergillus, 
and Fusarium species from both tube macrodilution and 
plate microdilution test methods conﬁ  rmed that the MIC 
and minimal fungicidal concentration (MFC) proﬁ  le for 
AmBisome is similar to that of AmB (Adler-Moore and 
Profﬁ  tt 1998; Anaissie et al 1991). The MIC of AmBisome 
ranged from 0.05 to 2.5 mg/L as compared with 0.1 to 
2.5 mg/L for AmB. Thus the integration of AmB into the 
liposome bilayer of AmBisome has little or no inhibitory 
effect on its MICs in vitro. The in vivo study conducted by 
Francis et al (1994) on neutropenic rabbits with pulmonary 
Figure 3 Proposed arrangement of AmB molecules (black) in the AmBisome bilayer.   This structure accounts for the observation of rapid ion ﬂ  uxes across the AmBisome 
bilayer in response to imposing a pH gradient from inside to outside. The individual AmB molecules form a “barrel” two of which ﬁ  t tail-to-tail to form a pore spanning the 
bilayer.   This structure is believed to contribute to the exceptional stability of AmBisome to loss of drug in buffer or plasma.International Journal of Nanomedicine 2006:1(4) 423
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aspergillosis designed to compare the clinical outcome with 
AmBisome at doses of 1, 5, and 10 mg/kg and conventional 
AmB at a dose of 1 mg/kg. All doses of AmBisome showed 
better survival than was seen with conventional AmB. 
Pulmonary haemorrhage was also reduced signiﬁ  cantly 
in all treatment groups, but the lesions were smaller and 
less striking in rabbits treated with AmBisome at 5 mg/kg 
(P < 0.001) or 10 mg/kg (P < 0.0001) compared to AmB 
(P < 0.01). In conclusion, AmBisome at 5 mg/kg was more 
efficacious than D-AmB. The antifungal effectiveness 
of AmBisome was also compared with AmB in cultured 
Langerhans cells infected with C. glabrata (Sperry et al 
1998). The Candida infected cells were incubated with 
AmB or AmBisome at 12.5 mg/L for up to 48 hours. Both 
AmBisome and AmB were found to be equally effective after 
48 hours, reducing the amount of viable fungus by 5 logs. 
Nevertheless, AmBisome was much less cytotoxic to the 
cultured Langerhans cells then AmB at this concentration. 
Effectiveness of increasing doses of AmBisome (8 to 
30 mg/kg/day) vs D-AmB (1 or 2 mg/kg/day) was also exam-
ined in neutropenic mice with hematogenous C. lusitaniae 
and C. krusei infection. Two of the infecting C. lusitaniae 
strains were resistant to AmB. Despite the fact that high 
doses of AmBisome were significantly more effective 
in infections due to AmB-susceptible isolates, there was 
no advantage of using AmBisome over the conventional 
preparation for infections due to AmB–resistant isolates 
(Karyotakis and Anaissie 1994).
AmBisome have proved to be an effective treatment 
for VL. In vitro, free AmB was 3–6 times more active than 
AmBisome against both Leishmania major promastigotes in 
culture and amastigotes in murine macrophages. In a BALB/c 
L. major model of cutaneous infection, AmBisome adminis-
tered once a day on 6 alternate days by the intravenous route 
produced a dose-response effect between 6.25 and 50 mg/kg 
(Yardley and Croft 1997). The intracellular fungus that has 
been found to be highly susceptible to AmBisome therapy 
in an immunosuppressed mouse model is Histoplasma 
capsulatum (Adler-Moore 1994). Low doses of Fungizone or 
AmBisome (4 doses of 0.3 or 0.6 mg/kg) were compared, and 
a higher dose of AmBisome (4 doses of 6 mg/kg) was also 
tested to resolve whether a higher dose gave a better thera-
peutic response. At the lower doses neither Fungizone nor 
AmBisome were predominantly effective. Twenty-four hours 
after the last lower dose treatments, colony forming units 
(cfu)/g of spleen were abridged by c. 2 logs compared with 
untreated controls, but regrowth was evident after 14 days 
in all cases. Conversely the higher dose of AmBisome 
(6 mg/kg) considerably reduced the cfu by 5 logs at 24 hours 
post- treatment compared with control.
Groll et al (2000) evaluated groups of uninfected and 
C. albicans-infected rabbits that were treated daily for 7 days 
with each of the three commercially available lipid formula-
tions of AmB as well as with D-AmB and showed that the 
AmBisome treated animals attained considerably higher drug 
concentration in the plasma of both the infected and unin-
fected groups compared with other formulations. Practically 
no drug (<0.1 mg/L) was found in the cerebrospinal ﬂ  uid 
(CSF) of any of the treatment groups. Nevertheless, there 
was a considerably higher concentration of AmB in the brain 
tissue itself in the AmBisome-treated groups than in groups 
receiving any of the other formulations, which in turn could 
be a reason for increased efﬁ  cacy. The tolerance and efﬁ  cacy 
of Fungizone (6 doses of 0.8 mg/kg, i.v.) were compared with 
those of AmBisome (6 doses of 0.8, 5 and 50 mg/kg, i.v.) 
and meglumine antimoniate (11 doses of 200 mg/kg i.p.) 
in a BALB/c mice model of VL induced by Leishmania 
infantum. A dose range study showed that administration of 
AmBisome at the well-tolerated doses of 5 or 50 mg/kg of 
body weight completely eradicated the parasites from the 
liver, spleen and lungs. At 0.8 mg/kg, AmBisome proved 
more efﬁ  cacious than Fungizone administered at the same 
dose and was capable to decrease the parasitic burden by at 
least 4–6 logs in the spleen and liver compared with untreated 
controls (Gangneux et al 1996).
Albert et al (1995) treated a mouse model of meningitis 
(caused by Cryptococcus neoformans) with multiple doses 
of AmB (0.3 mg/kg i.v. or 0.3 mg/kg i.p.) or AmBisome 
(1, 3, 20, or 30 mg/kg i.v.). Some animals were killed during 
the therapy, and culture results showed that 3 mg/kg AmB 
was more effective than 3 mg/kg of AmBisome for lowering 
fungal cfu in the brain. Nevertheless, when the animals were 
killed two weeks after the full six treatment regimen there 
was a 6 log increase in the number of C.neoformans cfu in the 
brains of mice treated with AmB. In contrast, in the AmBi-
some 3 mg/kg group, the cfu dropped by 1 log showing that 
AmBisome therapy was continue to kill the fungi even after 
treatment was stopped. In an efﬁ  cacy study of AmBisome by 
Berman et al (1986), 99% of Leishmania donovani parasites 
were eliminated from the liver and spleen of infected hamsters 
by one administration of 1.5–11 mg of AmBisome per kg. 
A total of 98%–99% of hepatosplenic parasites were elimi-
nated from squirrel monkeys by three administrations of 4 mg 
of AmBisome per kg. AmBisome was 170–750 times as active 
as antimony in hamsters, and approximately 60 times as 
active as antimony in monkeys. Recently Clemons et al (2000) International Journal of Nanomedicine 2006:1(4) 424
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challenged the immunosuppressed rabbits intracisternally 
with Coccidiodes immitis. Five days post-infection, groups 
of rabbits were treated with either ﬂ  uconazole (19 doses of 
80 mg/kg/day, p.o.), AmBisome (15 mg/kg i.v. 3 times a 
week for 3 weeks), AmB (1 mg/kg i.v. three times a week for 
3 weeks), or 5% glucose (control). All animals treated with 
ﬂ  uconazole, AmB and AmBisome were survived, whereas 
75% of the controls were died (P < 0.0005). The AmBisome-
treated group had 3- and 11- fold lower cfu in the brain and in 
the spinal cord, respectively, compared with the ﬂ  uconazole 
group, and 6- and 35- fold lower cfu, respectively, compared 
with the AmB treated group and AmBisome was found to be 
superior to either ﬂ  uconazole or AmB for the treatment of 
experimental coccidiodal meningitis.
In another study the efﬁ  cacy of AmBisome (5 doses: 
0.05, 0.1, 0.5, 0.8, and 3 mg/kg of body weight) was 
compared to that of Fungizone (4 doses: 0.05, 0.1, 0.5, and 
0.8 mg/kg) in a BALB/c mice model of VL induced by 
Leishmania infantum. AmBisome was about 3 times more 
active than the conventional drug against both strains (strain 
1 was obtained from an untreated patient, and strain 2 was 
obtained from a patient who had received 12.5 g of AmB 
over 3 years). Median effective doses (ED50) of AmBisome 
were 0.054 (strain 1) and 0.194 (strain 2) mg/kg. ED50 of 
conventional AmB were 0.171 (strain 1) and 0.406 (strain 2) 
mg/kg. Determination of drug tissue levels, 3 days after the 
last drug administration, showed the drug accumulation in 
hepatic and splenic tissues much higher after administra-
tion of AmBisome than after conventional AmB. A lack 
of toxicity was noted in all groups treated with AmBisome 
(Paul et al 1997).
In a pulmonary aspergillosis model in mice, immuno-
suppressed mice were challenged intranasally with 8 × 104 
A. fumigatus conidia (Olson et al 2000). Groups of seven 
infected mice were treated intravenously with AmBisome 
15 mg/kg, Abelcet 15 mg/kg, AmB 1 mg/kg, or 5% glucose 
daily for 4 days beginning 2 hours after challenge. All of 
the control mice were dead by day 5. The survival rate for 
groups treated with either Abelcet or AmB (Fungizone) 
was 29% on day 9 post-infection. However, the AmBisome 
treatment group had 86% rate of survival. Leenders et al 
(Leenders et al 1996) compared the efﬁ  cacy of AmBisome 
and the AmB in an unusual rat aspergillosis model. The 
rats were infected only in the left lung, and 40 h later they 
were treated with either AmB 1 mg/kg/day or AmBisome 
1 or 10 mg/kg/day for 10 consecutive days. Both AmB 
1 mg/kg/day and AmBisome 10 mg/kg/day increased 
survival; nevertheless, only AmBisome 10 mg/kg/day was 
able to cause a signiﬁ  cant diminution in cfu in the left lung 
(P = 0.003). Interestingly, distribution to the right lung 
was abridged in both of the AmBisome treatment groups, 
while conventional AmB was ineffective to prevent lung 
dissemination. Distribution to the liver and spleen was 
reduced by all treatments, but statistically signiﬁ  cant reduc-
tions were only observed in the AmBisome treatment groups 
(1 or 10 mg/kg/day). AmBisome 10 mg/kg/day completely 
prevented the distribution to the liver and spleen. Animal 
studies have revealed that AmBisome is also very effective in 
both treating and preventing fungal infections in the kidneys 
(Adler-Moore et al 1991; van Etten et al 1993; Garcia et al 
2000). In the prophylactic study, AmB levels in the kidneys 
of AmBisome-treated mice (5, 10, or 20 mg/kg) were ranged 
from 0.63 to 8.08 mg/kg 7 days after treatment (Adler-Moore 
and Profﬁ  tt 2002).
Clinical efﬁ  cacy and safety
AmBisome is much better endured than conventional AmB 
and is speciﬁ  ed in the treatment of severe systemic fungal 
infections where patients fail to respond to AmB, are intoler-
ant to its side-effect, or who have renal impairement prohibit-
ing the use of conventional drug. AmBisome was ﬁ  rst used 
clinically in 1987 when a heart transplant patient developed 
pulmonary aspergillosis, which due to nephrotoxicity could 
not be treated with conventional AmB (Katz et al 1990). 
After 34 days of treatment with AmBisome at 1 mg/kg/day, 
the infection was exterminated and no proof of reccurence 
was reported during a 16-month follow up period. Kidney 
function was also improved and acute side-effects such as 
fever and chills were not seen during therapy. Since then, 
AmBisome has been developed throughout the world and is 
currently licensed in more than 30 countries, including the 
US where it has sanctioned for empiric use (fever of unknown 
origin). In a controlled randomized trial, a short antifungal 
prophylaxis course of AmBisome was found to reduce the 
incidence of proven invasive fungal infections considerably 
during the ﬁ  rst month following liver transplantation surgery. 
AmBisome was well tolerated, although backache, throm-
bocytopenia and renal function impairment were reported 
in a few patients (Tollemar et al 1995). Clinical studies 
on immunocompromised adult and pediatric patients with 
invasive fungal infections, primarily candidiasis and aspergil-
losis, were designed to evaluate the efﬁ  cacy of AmBisome. 
The results obtained for AmBisome in these studies were 
promising and complete or partial response was seen. Speciﬁ  -
cally, the use of AmBisome in febrile neutropenic patients 
with suspected or conﬁ  rmed invasive mycoses resolved the International Journal of Nanomedicine 2006:1(4) 425
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fungal infection in 61% of the episodes. Treatment efﬁ  cacy 
was 77% for aspergillosis (Mills et al 1994). Ringden et al 
(Ringden et al 1991) also reported a favorable eradication 
rate of 83% for Candida and 41% for Aspergillus infections 
in immunocompromised patients treated with AmBisome. 
AmBisome was also effective in pediatric patients with 
similar disorders. A report on the serum and pulmonary con-
centrations of AmBisome in a patient with acute liver trans-
plant failure is also noteworthy. During follow-up of a patient 
with liver transplant failure and pulmonary aspergillosis, it 
was observed that peak and trough serum concentrations of 
AmB were increased, as were pulmonary concentrations of 
the drug (Heinemann et al 1997). The authors hypothesized 
that, in absence of a normally functioning liver tissue as a 
component of RES, the clearance function of the liver was 
diminished and that the clearance by the lung began to be 
important (Schmidt et al 1998).
The multicenter study by Meunier et al (1991) included 
126 patients receiving 133 episodes of AmBisome treat-
ment. The majority of these patients had failed previous 
conventional AmB therapy due to toxicity. AmBisome 
was administered for 21 days at an average daily dose of 
2.1 mg/kg (range = 0.45–5 mg/kg). Hypokalaemia was 
the most common side-effect observed in 24 cases. In 
17 episodes, creatinine was initially high, but returned to 
normal. Glutamyloxaloacetate transaminase became elevated 
in 19 instances, and elevation in alkaline phosphatase was 
observed in 22 instances. Nevertheless there was no report 
of discontinuation of AmBisome therapy due to adverse 
side-effects. Thus, AmBisome was well tolerated even 
in severely ill patients. Walsh et al (1998) administered 
AmBisome to 36 febrile neutropenic patients for empirical 
antifungal therapy at doses of 1, 2.5, 5, or 7.5 mg/kg. No 
fungal infections were observed, suggesting that AmBisome 
was effective in preventing breakthrough fungal infections. 
A more recent report including 687 febrile neutropenic 
patients and comparing D-AmB with AmBisome as empirical 
therapeutic agents validated the previous data. It was again 
shown that AmBisome was as effective as the conventional 
drug and was associated with fewer breakthrough fungal 
infections and fewer toxic reactions (Walsh et al 1999).
Recently AmBisome safety was judged in a series of 
187 transplant recipients. AmBisome was administered 
daily at dose levels between 1 and 4 mg/kg for a median 
of 11 days (range of 1–112 days). Side effects including 
allergic reaction, low back pain during infusion, dyspnea, 
low serum potassium, and nausea and vomiting ascribed 
to AmBisome therapy were observed in only 7% of 
the cases and resulted in discontinuation of therapy in 
6 cases. In this context, with patients receiving a variety of 
potentially toxic drugs, the AmBisome side-effect proﬁ  le 
was mild and controllable in the vast majority of patients 
(Ringden et al 1994). Recent multicenter randomized trials 
compared D-AmB at 1 mg/kg/day to AmBisome at 1 and 
3 mg/kg/day in adults (Prentice et al 1997) and children 
(Hann et al 1995) with febrile neutropenia unresponsive to 
broad spectrum antibiotics. A group of 193 adult patients 
was prospectively randomized into the three treatment 
groups. Fifty-two patients had conﬁ  rmed mycosis, seven 
were not classiﬁ  able and the rest were stratiﬁ  ed as having 
fever of unknown origin (FUO). The adult study showed 
significantly lower adverse events for the AmBisome 
groups. D-AmB showed 50% nephrotoxicity compared with 
16% and 18% showed by AmBisome 1 and 3 mg/kg/day 
groups (p = 0.001). Also hypokalemia was considerably 
less in the AmBisome cohorts. A paediatric study created 
a similar picture, but differed in detail. Nephrotoxicity was 
lower in the AmBisome compared with D-AmB but the 
differences were not statistically signiﬁ  cant. Considerable 
advantages were seen for AmBisome therapy in incidences 
of hypokalemia, treatment delay, and resolution of fever. 
Davidson et al measured the optimum dose and schedule 
for AmBisome treatment of VL. A group of 88 patients, 
mostly children was treated with 4 different dose regimens. 
Eighty-four patients were completely cured of their disease 
by the initial treatment course lasting 10 days (4 or 5 days 
daily treatment at 3 or 4 mg/kg/day and 1 follow up on 
day 10). Four relapsing children received an additional 
10-day course of treatment at 3 mg/kg/day which cured 
them all (Davidson et al 1996). This study is outstanding 
not only for the short course treatment and high cure rate 
of VL patients, but also for the favorable safety proﬁ  le (no 
signiﬁ  cant adverse events) (Schmidt et al 1998).
The efﬁ  cacy and safety of 3 regimens of AmBisome in 
the treatment of Indian VL were compared in a prospective 
open randomized trial. Thirty parasitologically conﬁ  rmed 
patients were randomly divided into 3 equal treatment groups; 
group 1 received AmBisome 2 mg/kg on days 1, 2, 3, 4, 5, 6, 
and 10 (total dose 14 mg/kg); group 2 received AmBisome 
2 mg/kg on days 1, 2, 3, 4, and 10 (total dose 10 mg/kg); 
group 3 received the same dosage on days 1, 5 and 10 (total 
dose 6 mg/kg). Clinical cure resulted in all patients by day 24. 
Haemoglobin, white blood cell count, body weight and serum 
albumin level improved on day 24 and became normal by 
day 180. No patient relapsed within 12 months of follow up 
(Thakur et al 1996).International Journal of Nanomedicine 2006:1(4) 426
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Immunoliposomes
The current encouraging progress regarding lipid-based 
formulations of AmB is the development of novel liposomes 
with speciﬁ  c properties. One of these, “immunoliposomes”, 
contains fungus-speciﬁ  c antibodies on their surface which 
target them directly to the fungal cells. AmB coated with 
immunoliposomes abridged mortality appreciably in 
mice with invasive pulmonary aspergillosis as compared 
conventional L-AmB (100% vs 16.7% survival rate). AmB 
coated with immunoliposomes was also more effective than 
AmB integrated with long-circulating liposomes (100% vs 
83.3% survival rate) (Otsubo et al 1998). Likewise, treatment 
of murine candidiasis and cryptococcosis with AmB 
integrated with immunoliposomes proved enhanced activity 
compared to that with conventional L-AmB (Belay et al 1991; 
Dromer et al 1990).
Long-circulating liposomes
The other novel delivery system, ‘long circulating liposomes’ 
are coated with polyethylene glycol (PEG), resulting in 
a sterically stabilized surface. Since the time period to 
reside in circulation is prolonged by the structural nature of 
long-circulating liposomes, more intact liposomes can get 
localized at the site of infection, thus enhancing the in vivo 
efﬁ  cacy (Storm and van Etten 1997). In an experimental 
murine model of systemic candidiasis, AmB integrated 
with long-circulating liposomes (PEG-L-AmB) proved to 
be more effective than the conventional L-AmB (van Etten 
et al 1995; van Etten et al 1998). Nevertheless, intracellular 
antifungal activity of PEG-L-AmB assessed in C. albicans 
infected murine peritoneal macrophages was as low as that 
of conventional L-AmB, while it was higher for D-AmB 
(van Etten et al 1998).
Other lipid based 
nanomodiﬁ  cations
Lipid nanospheres
Studies on efﬁ  cacies of NS-718, AmB encapsulated in lipid 
nanosphere are in progress. Lipid nanosphere is composed 
of equal amounts of egg lecithin and soybean oil. The 
carrier potentials of lipid nanosphere are characterized by 
lower uptake by the reticuloendothelial system and good 
distribution to the sites of inﬂ  ammation. When equivalent 
dose of NS-718 or Fungizone were injected intravenously 
into rats, the plasma AmB level yielded by NS-718 was 
higher than Fungizone at all time up to 2 hours. In a tissue 
distribution study, the concentration in the liver after the 
injection of NS-718 was lower than that of Fungizone. This 
characteristic of NS-718 to avoid uptaking by reticuloendo-
thelial system (RES) is related to high plasma concentration 
of AmB. These results suggest that NS-718 have several 
unique characteristics different from other lipid formula-
tions for the treatment of fungal infections (Seki et al 1994; 
Tomii 2002). In another study NS-718 was found to be more 
effective than D-AmB or L-AmB against clinical isolates 
of C. albicans and Aspergillus fumigatus. NS-718 was 
well tolerated and showed improved survival markedly at 
equivalent doses in treating pulmonary aspergillosis in rat. 
Increased activity was also supported by pharmacokinetic 
study (Kohno et al 1995).
Fukui et al investigated whether AmB retained its 
antifungal activity in NS-718 (Fukui et al 1996). Antifungal 
activity of NS-718 against Candida albicans was similar 
to that of AmB and Fungizone. However, the antifungal 
activity of L-AmB was decreased. Thus, NS-718 maintained 
the potent activity of AmB against fungal cell even though 
the AmB was incorporated into LNS particles. Hossain 
et al compared the direct cytotoxicity of NS-718 with 
that of Fungizone in human proximal tubule cells in vitro 
and showed decreased cytotoxicity of NS-718 (Hossain 
et al 2000). These results showed an increased selectivity 
between toxicity of NS-718 against mammalian cells and 
antifungal activity.
In vitro and In vivo antifungal efﬁ  cacy of NS-718 was 
also studied in pulmonary cryptococcosis in mice. NS-718 
was found to have better in vitro efﬁ  cacy against clinical 
isolates of Cryptococcus neoformans than other AmB 
formulations, was well tolerated, and efﬁ  cacy was much 
higher than that of D-AmB or L-AmB in treating pulmonary 
cryptococcosis in mice (Hossain et al 1998). In vivo anti-
fungal efﬁ  cacy of NS-718 was also studied in invasive pul-
monary aspergillosis in rats (Otsubo et al 1999). The results 
showed that NS-718 was effective in treating pulmonary 
aspergillosis in rats, but equivalent doses of Fungizone and 
L-AmB were either lethally toxic or ineffective.
In a rat model of localized candidiasis, LNS-AmB 
signiﬁ  cantly inhibited the growth of C. albicans in the pouch, 
whereas AmBisome did not, even though the AmB concen-
trations in the pouch were similar. This difference in anti-
fungal activity between LNS-AmB and AmBisome was also 
found in vitro. That is, the antifungal activity of LNS-AmB 
against C. albicans was similar to that of Fungizone and 
dimethyl sulfoxide-solubilized AmB, while AmBisome 
showed weaker antifungal activity than did other formulations 
(Figure 4). In a mouse model of systemic candidiasis, International Journal of Nanomedicine 2006:1(4) 427
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LNS-AmB (1.0 mg/kg) greatly improved the survival rate 
(Figure 5) and was therefore much more effective than 
AmBisome (8.0 mg/kg) (P<0.05) or Fungizone (1.0 mg/kg) 
(P<0.01) (Fukui et al 2003).
Cochleates
Cochleates are stable phospholipid-calcium precipitates 
comprised mainly of phosphatidylserine. The in vivo 
therapeutic efﬁ  cacy of cochleates containing AmB (CAmB) 
administered orally was evaluated in a mouse model of 
systemic candidiasis. The fungal tissue burden in kidneys 
and lungs was assessed, and a dose-dependent reduction in 
C. albicans from the kidneys was observed, with a maximum 
3.5-log reduction in total cell counts at 2.5 mg/kg/day. 
However, complete clearance of the organism from the lungs, 
resulting in more than a 4-log reduction, was observed at the 
same dose. (Santangelo et al 2000).
In the study by Zarif et al (Zarif et al 2000) CAmB 
protect ICR mice infected with C. albicans when the agent 
is administered intraperitoneally at doses of as low as 
0.1 mg/kg/day. In a tissue burden study, CAmB, Fungizone, 
and AmBisome were effective in the kidneys, but in the spleen 
CAmB was more potent than Fungizone at 1 mg/kg/day and 
was equivalent to AmBisome at 10 mg/kg/day.
LNS-AmB
AmBisome
AmB in medium (μg/mL)
DMSO-solubilized AMB
Funglzone
O
D
5
4
0
0.24
0.20
0.16
0.12
0.08
0.04
0.001 0.01 0.1
Figure 4 Antifungal activity of LNS-AmB, Fungizone, AmBisome, and DMSO-solubilized AmB in vitro.   The growth inhibition of C. albicans was measured by the change in 
optical density at 540 nm in SD-MOPS broth after a 24-h incubation at 35°C. Results are the mean of two experiments. 
Adapted from Fukui et al (2003).
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Figure 5 Survival of mice infected with C. albicans and treated with LNS-AmB, Fungizone, or AmBisome. Treatment was started 4 hours after fungal inoculation. +, P<0.05 
compared with AmBisome; #, P<0.01 compared with Fungizone.
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Emulsome: a novel nano lipid particle
Emulsomes are a new generation colloidal carrier system in 
which the internal core is made of solid fats and triglycerides 
which is stabilized by high concentration of lecithins in the form 
of o/w emulsion (Amselem et al 1994). The effects of emul-
somes, nanosize range lipid particles containing AmB (EAmB) 
were compared with the reference formulation Fungizone and 
with the commercial preparation AmBisome. Both Fungizone 
and EAmB had a minimum inhibitory concentration (MIC) 
of 0.039 μg/ml against C. albicans ATCC10231, whereas the 
MIC for AmBisome was considerably higher (0.156 μg/ml). 
However, the yeasts were more rapidly killed by Fungizone 
than by EAmB in spite of similar MIC values. The killing of 
C. albicans was delayed when EAmB was used. In a tissue 
culture model and in mice, the incorporation of AmB into 
emulsomes resulted in a considerable reduction of toxicity in 
comparison with Fungizone. For comparison of the in vivo 
effect of the preparations, a mouse model of systemic infection 
with C. albicans was used. All preparations were able to reduce 
the fungal burden in the liver and kidneys in comparison with 
control animals treated with isotonic saline. AmBisome was 
more efﬁ  cient in the reduction of the fungal burden of the liver 
than EAmB and Fungizone, even when applied in a similar 
dosage of 1 mg/kg. In the kidneys, EAmB and Fungizone were 
slightly more effective than AmBisome. Therefore the incorpo-
ration of AmB into nanosize lipid particles was able to reduce 
toxicity without loss of efﬁ  ciency (Kretschmar et al 2001).
In our laboratory we have developed and evaluated 
AmB loaded emulsomes for the treatment of VL. By virtue 
of solidiﬁ  ed or semisolidiﬁ  ed internal oily core it provided 
a better opportunity to load AmB in high concentration. 
In vivo studies on L. donovani infected hamsters showed 
better results for AmB emulsomes as compared to control 
(D-AmB, Mycol) (Figure 6).
The maximal percentage of parasite suppression (55.7%) 
was obtained with 0.5 mg/kg of AmB loaded trilaurin emul-
somes (TLEs). Tristearin emulsomes (TSEs) showed 40.7% 
parasite suppression at the same dose whereas only 33.6% 
of parasite suppression was observed with relatively higher 
dose (1 mg/kg) of D-AmB or Mycol (Table 2).
Table 2  Activity of emulsome formulations against L. donovani in hamsters infected for 30 days
S.No Formulation 
code
% drug 
entrapment
Dosage given 
(mg/kg)
% parasite 
suppression
1 Mycol – 1 mg/kg 33.6%
2 TLEs 80.1 0.5 mg/kg 55.7%
3 TSEs 84.7 0.5 mg/kg 40.7%
A
D
B
C
Figure 6 Photographs showing geimsa stained splenic smears of hamster treated with emulsomes and control formulations. A-untreated control group; B-Mycol (AmB for 
injection) treated group; C-TLEs orTrilaurin based emulsomes treated group; D-TSEs or Tristearin based emulsomes treated group.International Journal of Nanomedicine 2006:1(4) 429
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Future directions
Fungal infections are on the rise worldwide, particularly as 
the population of immunocompromised patients continues 
to grow. By itself, AmB is an effective antifungal and anti-
leishmanial agent, though it is highly toxic, particularly to 
the kidney. The goal of these lipid formulations of the AmB 
is to transport the drug throughout the body without expos-
ing it to sensitive organs and tissues and then to deliver it in 
concentrated dosage to the target site. To a certain extent all 
the lipid formulations accomplish this goal. The maximum 
tolerable dose of AmB is about 1 mg/kg/day. However these 
lipid formulations allow physician to go up to 5 times the 
dose of AmB without increasing infusion related toxicities. 
All the lipid formulations of AmB demonstrate improved 
efﬁ  cacy, primarily because of the higher administered dose, 
and reduced kidney toxicity, compared to AmB. As such the 
future of these lipid formulations is bright and it is appar-
ent that these lipid based products will replace AmB as the 
mainstays in the treatment of systemic fungal infections and 
leishmaniasis.
Targeting AmB using the colloidal carrier systems, 
ie, liposomes, emulsomes, or nanospheres etc to the sites 
of infection could readily be utilized in terms of their 
industrial application as this can provide a better therapy 
mode for treatment of systemic fungal infections and 
leishmaniasis in comparison with currently available 
drug regimen in the market for these respective diseases. 
High loading efﬁ  ciency and protracted release proﬁ  le may 
further reduce the dose size and dose frequency. Further the 
easier ligation of surface speciﬁ  c ligands could enhance the 
target speciﬁ  city and performance efﬁ  ciency. Thus the drug 
AmB, which is well known for its effectiveness however, 
compromised due to its contraindicated manifestations, 
can safely be administered for effective cure of infective 
diseases. Nevertheless, these nanocarriers may provide 
curable disposition of systemic microbial infections. 
Moreover, the colloidal nature of these nanocarriers leads 
to their passive accumulation in pathogen harbouring or 
infected macrophages. More advances in nanotechnology 
will hopefully result in more efﬁ  cient and less toxic AmB 
therapeutic regimens.
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